Zymeworks Inc. (NASDAQ: ZYME) is a Healthcare company (Biotechnology) with a market capitalization of $1.8B. The Maz Rating grades it against the other companies in its sector.
Zymeworks Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $25.84, Zymeworks Inc. trades at 38.3x trailing earnings, 6.7x sales and 7.1x book value, with an EV/EBITDA of 41.1. Over the last twelve months it generated about $268M of revenue and $47M of net income. It runs a gross margin of 98.3%, an operating margin of 16.6% and a net margin of 16.3%. It shows return on equity of 22.5%, return on invested capital of 4.3% and a free cash flow yield of -6.2%. On the balance sheet: a debt-to-equity ratio of 2.52 and a current ratio of 3.30. Over the past 52 weeks the share price ranged from $21.52 to $31.97, with a beta of 1.17.
Zymeworks Inc. does not currently pay a dividend.
23 Wall Street analyst ratings cover the stock: 21 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Zymeworks Inc. (ZYME) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 29.8% / 30% · (Cash+Inv) / Mkt Cap (36m) 5.02% / 30% · Interest income / Revenue 0.96% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 29.8% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 5.02% / 33% · Receivables / Mkt Cap (36m) 20.7% / 49% · Interest income / Revenue 0.96% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 29.8% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 5.02% / 33.33% · Receivables / Mkt Cap (24m) 20.7% / 33.33% · Interest income / Revenue 0.96% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 35.7% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 40.2% / 33.33% · Receivables / Avg Assets (4Q) 17.9% / 33.33% · Interest income / Revenue 0.96% / 5% | Fail |
| FTSE | Debt / Total Assets 50.8% / 33.33% · (Cash+ST Inv) / Total Assets 8.54% / 33.33% · (Cash+Recv) / Total Assets 43.7% / 33.33% · Interest income / Revenue 0.96% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Zymeworks Inc. (ZYME) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. Zymeworks Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.96% of each dividend: Zymeworks Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.